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Antitumor lipids (ATL) form a family of synthetic compounds capable of selectively inducing 
cell death in tumor cells. The prototype molecule of this family is edelfosine and in contrast to 
other antitumoral drugs, it acts on cell membranes rather than on DNA. The apparent 
selectivity on tumor cells seems to be related to a preferential accumulation of the drug in 
cancer cells involving chlolesterolrich lipid raft.However, in spite of these properties, so far 
the clinical applications of ATLs in cancer therapy have been very limited. A broader clinical 
application of these compounds would require the search of more clinically active 
compounds, and a much better understanding of the mechanisms by which some tumors are 
more sensitive than others. to ATLs. To answer these questions using tumor tissue culture 
cell lines or murine models can be technically challenging. Sánchez-Blanco and colleagues 
have used the nematode Caenorhabditis elegans as a starting point to cope with these 
limitations. C. elegans has been a model organism in biology for more than 40 years and can 
now be found in laboratories worldwide. Furthermore, it has become widely used as a model 
for human diseases, because it provides a cheap and fast alternative to traditional more 
expensive and time-consuming models such as mouse and rat. Sánchez-Blanco et al. have 
found that edelfosine has a selective lethal effect to the C. elegans embryo without affecting 
the overall physiological status of adult worms. The embryo is composed of proliferating cells 
while the adult soma is composed of quiescent cells and therefore this result demonstrate 
that in C. elegans ATLs seem to maintain the selective killing ability that is the basis for their 
clinical application. Moreover, previous research in cultured mammalian cells suggested that 
a main factor for this selectivity was related to the high cholesterol content of cancer cells. As 
Sánchez-Blanco et al. have noted, one of the reasons for the selective effect of edelfosine in 
embryos was related to the high cholesterol content found in the embryo. Moreover, thanks 
to the fact that C. elegans cannot synthesize cholesterol de novo, and it has to be provided 
on culture medium, Sánchez-Blanco et al, using conditions that modified the cholesterol 
concentration in the worm growth medium, were able to demonstrate that the effect of ATLs 
in worms was directly related with the cholesterol concentration. The use of C. elegans in 
drug discovery offers several advantages and Sánchez-Blanco and colleagues show many of 
them in this report. Firstly, they demonstrated that C. elegans could be used to screen in vivo 
screen for additional more active ATLs. As a proof of principle they have compared the 
efficiency of different ATLs and they have found that the worm model mimicked the 
differential sensitivity to ATLs observed in various tumor cell lines, opening the door to the 
use of worms for the design of more active drugs. Secondly, they have taken advantage of 
the wellestablished role of C. elegans as workhorse of hard-core geneticists, who have 
developed elaborate genetic tools. Using an educated choice of mutants, Sánchez-Blanco et 
al have found that mutants in the insulin/IGF-like signaling  pathway displayed a marked 
resistance to edelfosine. Strikingly, they were able to translate this finding to mammalian cells 
and they showed that inhibition of Akt1, one of the components of this pathway, in a human 
tumor cell line also renders the treated cells less sensitive to edelfosine. Again, this finding 
opens the way to understand the molecular basis of ATL sensitivity and resistance in tumor 
cells. In summary, Sánchez-Blanco and colleagues showed in this elegant piece of work that 
the mechanisms driving embryonic lethality in C. elegans upon ATL treatment can be 
extrapolated to human models. This work further supports the use of C. elegans in facilitating 
the identification of new targets and strategies in the fight against cancer processes. 
It also reinforces the need for genetic screens and studies of model organisms to discover 
novel signaling pathways that reveal possible therapeutic targets. 
 
 
 
